COVID-19 INDUCES SENESCENCE AND EXHAUSTION OF T CELLS IN 1 PATIENTS WITH MILD/MODERATE AND SEVERE DISEASE DURING A 2 SEVEN-DAY INTERVAL 3 RODRIGO BALSINHA PEDROSO¹, LUCAS HANIEL ARAÚJO VENTURA², 4 LÍCIA TORRES², GIOVANNA CALIMAN CAMATTA², FELIPE CAIXETA², 5 LEANDRO SOUZA NASCIMENTO², CATARINA MOTA¹, ANA CATARINA 6 MENDES¹, FILIPA RIBEIRO¹, HENRIQUE CERQUEIRA GUIMARÃES ⁴, RAFAEL 7 CALVÃO BARBUTO⁴, GABRIELA SILVEIRA-NUNES³, ANDREA TEIXEIRA-8 CARVALHO⁵, LUIS GRAÇA^{1*}, ANA MARIA CAETANO FARIA^{2*}. 9 10 ¹ Instituto de Medicina Molecular, Faculdade de Medicina (IMM), Universidade de 11 Lisboa, Lisboa, Portugal. 12 ² Departamento de Bioquímica e Imunologia, Instituto de Ciências Biológicas (ICB), 13 Universidade Federal de Minas Gerais (UFMG), Belo Horizonte, MG, Brazil. 14 ³Departamento de Medicina, Universidade Federal de Juiz de Fora, Campus Governador 15 16 Valadares (UFJF-GV), MG, Brazil. ⁴ Hospital Risoleta Tolentino Neves, Belo Horizonte, MG, Brazil 17 ⁵ Instituto de Pesquisa René Rachou, Fundação Oswaldo Cruz (FIOCRUZ-MG), Belo 18 19 Horizonte, MG, Brazil. 20 * Joint senior authors. 21 22 Corresponding authors: Luis Graca (Igraca@medicina.ulisboa.pt) and Ana M.C. Faria (anacaetanofaria@gmail.com) 23 24 25 Abstract 26 Risk factors for the development of severe COVID-19 include several comorbidities, but age was the most striking one since elderly people were disproportionately affected 27 by SARS-Cov-2. Major drivers that can explain this markedly unfavourable response in 28 29 the elderly are inflammaging and immunosenescence. Recent reports have shown that 30 the relationship between immunosenescence and COVID-19 can be bidirectional, since hospitalized patients with severe COVID-19 have an accumulation of senescent T cells 31 suggesting that immunosenescence can be also exacerbated by SARS-CoV-2 infection. 32 Therefore, the present work was designed to examine the emergence of 33 immunosenescence in a longitudinal study in two distinct cohorts of COVID-19 34

- patients, and to determine whether the senescence alterations were restricted to severe
- 36 cases of the disease. Our data, with patients from Portugal and Brazil, identified their
- 37 distinctive inflammatory profile and provided evidence of increased frequencies of
- 38 senescent and exhausted T cells within a seven-day period in patients with mild to
- 39 severe COVID-19. These results support the view that SARS-CoV2 infection can
- 40 accelerate immunosenescence in both CD4 and CD8 T cell compartments in a short
- 41 period of time.

45

47

48

- 43 **Key words:** COVID-19, immunosenescence, T cell exhaustion, T cell senescence,
- 44 inflammatory cytokines, inflammaging
- 46 **Running Title:** COVID-19 induces rapid T cell senescence.

Introduction

- 49 Since 2019 when it first started in China, the Corona Virus Disease-2019 (COVID-19)
- 50 pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-Cov-
- 51 2) has been responsible for the death of more than 6 million people worldwide (WHO,
- 52 2020a). Clinical manifestations of COVID-19 range from asymptomatic to severe
- 53 pneumonia associated with extensive immune-inflammatory response, a clinical
- 54 condition that can lead to multiorgan failure and prolonged complications (Osuchowski
- 55 et al, 2021).
- 56 Risk factors for the development of severe COVID-19 include obesity, diabetes, high
- 57 blood pressure, male sex, and age, with the latter being the most striking, since elderly
- 58 people were disproportionately affected by SARS-Cov-2 (Li et al, 2020; Guo et al,
- 59 2020; Rahman & Sathi, 2020; Xu & Chen, 2020; Wu et al, 2020; Zhou et al, 2020).
- 60 Among the reasons for this markedly unfavourable response in the elderly,
- 61 immunosenescence and inflammaging are major drivers of this outcome (Mueller,
- 62 McNamara, Sinclair, 2020; Camell et al, 2021). Immunosenescence is the aging of the
- 63 immune system and is mainly characterized by a decrease in naïve T cell numbers
- together with an accumulation of CD4⁺ and CD8⁺ memory and terminal effector T cells,
- 65 resulting in increased vulnerability to infections and impaired response to vaccination
- 66 (Hassoueneh et al, 2016; Fulop et al, 2018; Aiello et al, 2019). Moreover, aging T
- 67 lymphocytes like other senescent cells tend to develop a secretory-associated senescent
- 68 phenotype (SASP), characterized by the production and secretion of IL-6, IL-1, IL-8,

69 IL-18, and TNF along with other inflammatory mediators. Senescent cell accumulation as well as other aging-related disturbances (mitochondrial dysfunction, dysbiosis of 70 microbiota, innate immune responses) lead to a chronic low grade inflammatory state 71 72 known as *inflammaging* (Fulop et al, 2018; Batista et al, 2020; Heath and Grant, 2020). 73 Continuous immune dysregulation induced by prolonged exposure to infectious and 74 non-infectious antigens can also drive immune cell aging, since the accumulation of 75 inflammatory mediators secreted in response to consecutive infections further 76 contributes for the impairment of the adaptive immune response, boosting 77 immunossenescence and *inflammaging* (Fulop et al, 2018; Goronzy & Weyand, 2019; Elyahu & Monsonego, 2021). Chronic infections, including those caused by the human 78 79 cytomegalovirus (CMV), HIV, hepatitis B virus (HBV) and human papillomavirus (HPV), are sources of constant stimulation to the immune system, resulting in the 80 81 accumulation of terminally differentiated senescent T cell populations and, 82 consequently, immunesenescence (Solana et al, 2012; Fulop, Larbi, Pawelec, 2013). 83 Similarly, although it is not a persistent infection, SARS-Cov-2 can also trigger the 84 accumulation of exhausted and senescent T cell phenotypes due to its extensive 85 activation and clonal expansion (Diao et al, 2020; Zheng et al, 2020b). Recent 86 publications have shown that severe COVID-19 patients presented an increased 87 frequency of terminally differentiated CD4 and CD8 T cells when compared to controls matched for sex and age (Zheng et al, 2020a; Arcanjo et al, 2021). However, there is no 88 longitudinal study clearly demonstrating that SARS-CoV-2 infection leads to 89 accelerated immunosenescence in distinct populations and in different forms of 90 91 COVID-19. 92 In this study, we investigated the evolution of the inflammatory response and 93 immunosenescence of COVID-19 patients from Belo Horizonte, Brazil, and Lisbon, 94 Portugal. Blood samples were collected during ambulatory care or hospitalization, and one week later, allowing the evaluation of the impact of the disease over a period of 95 seven days. Our results showed that SARS-CoV-2 infection induces T cell senescence 96 97 in both populations in a short period of time, in both moderate and severe cases, with 98 this effect being more prominent in the latter.

Materials and Methods

101 Ethics statement

102 The research protocol was approved by the National Research Ethics Commission 103 (CONEP # 5.190.260) of Brazil and by the Lisbon Academic Medical Center Ethics 104 Committee (ref. no. 306/20). The study was conducted in accordance with the Helsinki 105 Declaration for research involving humans. All participants, including healthy controls, agreed to participate voluntarily in this study without financial support and signed an 106 107 informed consent. 108 109 Study design 110 This longitudinal study was performed at two healthcare centres: Centro Hospitalar 111 Universitário Lisboa Norte (CHULN) in Lisbon, Portugal, and Hospital Risoleta 112 Tolentino Neves in Belo Horizonte, Brazil. Non-vaccinated patients were recruited 113 within the first three days of hospitalization or while in ambulatory care, after 114 presenting a positive nasopharyngeal swab test for SARS-CoV-2 by real-time reverse transcriptase-polymerase chain reaction (RT-PCR) performed upon admission at the 115 116 health care units. A total of 20 infected patients from Lisbon and 10 from Belo Horizonte agreed to participate in this study. For the longitudinal follow-up, blood 117 samples were collected at the time of enrolment (T0) and seven days later (T7). Each 118 119 city had a control group formed according to the following criteria: testing negative for 120 COVID-19 in the RT-PCR test and not having presented any symptom the week before blood sample collection. Individuals with prior inflammatory diseases, such as cancer 121 122 and renal failure were excluded. Data collection was carried out between August and 123 October 2020 in Lisbon and June and August in Belo Horizonte. 124 Disease severity classification was based on the WHO criteria (WHO, 2020b). Mild 125 cases were considered asymptomatic or those treated in an outpatient clinic. Moderate 126 cases included hospitalized patients without oxygen support or using a low to moderate flow oxygen by mask or nasal prongs. Severe cases were characterized as the need for 127 high flow oxygen, mechanical ventilation, vasopressors, dialysis, or extracorporeal 128 129 membrane oxygenation (ECMO) (WHO, 2020b). 130 Blood collection and isolation of PBMCs 131 Peripheral blood mononuclear cells (PBMCs) were obtained by blood collection from 132 133 COVID-19 patients and healthy controls using heparinized vacuette tubes. The 134 purification was attained by Ficoll gradient (Histopaque-1077; Sigma, cat #10771) 135 centrifugation at room temperature, in a 1:2 ratio, for 40 minutes, at 600xg and without

- brake-induced end-centrifugation deceleration phase. After that, the PBMCs were
- 137 collected and washed with Roswell Park Memorial Institute (RPMI) 1640 basal
- medium. Red blood cells were lysed using a lysis buffer. Cells were counted and stored
- in fetal bovine serum supplemented with 10% dimethyl sulfoxide at -80 °C until further
- use. Blood serum was also obtained by centrifuging whole blood collected in sera tubes
- for 10 minutes at 500xg.

157

- 143 *Immunophenotype by polychromatic flow cytometry*
- PBMCs (1×10⁶) were first stained with LIVE/DEAD fixable aqua dead cell stain
- 145 (ThermoFisher Scientifc, cat #L34957) and antibodies fluorophore-conjugated human to
- surface markers. anti-CD8 (RPA-T8, cat# 562282), -CD4 (SK3, cat# 557852), -CD25
- 147 (M-A251, cat# 555432), -CD278 (ICOS; DX29, cat# 562833), -CD57 (NK-1, cat#
- 148 563896), -CD279 (PD-1; EH12.1, cat# 563245), -TIGIT (741182, cat# 747840), -CD28
- 149 (CD28.2, cat# 561368), -CD45RO (cat# 304234), -CD3 (cat# 317340), -CCR7 (cat#
- 150 353216) and -KLRG1 (cat# 138427).
- 151 After the surface staining, cells were fixed and permeabilized using the
- Foxp3/Transcription Factor Staining Buffer Set from eBioscience (cat #00-5523-00)
- and stained for -Foxp3 from ImmunoTools (3G3, cat# 21276106). Single colors for
- 154 fluorescence compensation were prepared with antibody capture compensation beads
- (BD Biosciences). Cell samples were acquired in a BD LSRFortessa cell analyzer (BD
- Biosciences) coupled to computers with DIVA and FlowJo-10 software (Tree Star).
- 158 Luminex-Multiplex measurement of serum cytokines, chemokines, and growth factors
- 159 A Bio-Rad Laboratories kit (Bio-Plex Pro Human Cytokine Standard) was used to
- analyse multiple serum mediators simultaneously with the Bio-Plex 200 system from
- 161 Bio-Rad, following storage and processing protocols standardized by the Laboratory of
- 162 Biomarkers (IRR-FIOCRUZ/MG). Samples were transported and stored at a
- temperature of -80°C. Analyzes were performed using BioplexTM xPONENT version
- 3.1 software (Bio-Rad) and included the following panel of analytes: IL-1β, IL-1ra, IL-
- 2, IL-4, IL-5, IL-6, CXCL-8 (IL-8), IL-10, IL-12p70, IL-13, GM-CSF, IFN-γ, CCL-2
- 166 (MCP-1) and TNF-α. The panel of biomarkers included in the kit and their standard
- settings is presented in Supplementary Table 1.
- 169 Statistical analysis

170 Statistical analyses were performed using GraphPad Prism 8.0 software (GraphPad 171 Software, San Diego, CA, USA). All data acquired from Luminex-Multiplex were 172 converted to logarithmic scale to normalize the data, and a lognormality test was 173 performed to confirm data normality. Wilcoxon test was applied in non-parametric data to compare samples of the same patient at T0 and T7. Student's t-test was used for 174 175 analysing parametric data. 176 Radar plots highlight the contribution of different cytokines to immunological profile. 177 This analysis allows to convert quantitative cytokine measurements into a categorical 178 variable of low and high cytokine producers as previously proposed by Luiza-Silva et al. (2011). Briefly, this approach categorizes each subject as "Low" or "High" cytokine 179 180 producer, taking the global median value as a specific cut-off edge for each cytokine. 181 For the calculation of the global median the whole universe of data obtained for the 182 groups was considered. Following data categorization, the frequency of "High Cytokine Producers" was calculated for each group. On radar charts, each axis represents the 183 184 percentage (%) of volunteers categorized as "High Cytokine Producers" in each group. 185 Then, connecting the values of each axis forms a central polygonal area that represents 186 the immunological profile. Relevant productions were considered when the percentage 187 of "High Cytokine Producers" of a given cytokine was greater than 50%. The correlation matrix was built using the cor() function of the statistical analysis 188 189 package stats v3.6.2 available in the R v4.0 environment. Spearman's correlation was 190 used considering the non-parametric nature of the data, considering only correlations 191 with p<0.05. 192 Statistical analysis of data on frequencies of T cell subsets obtained by flow cytometry 193 was performed using the nonparametric Wilcoxon rank-sum. P < 0.05194 **Results** 195 The study included 20 individuals with severe cases of COVID-19 from Lisbon, and 8 196 197 individuals with mild to severe cases from Belo Horizonte. The median age of 198 individuals in the infected groups was 69 (IQR 60.0 – 84.3 years) and 42.5 years old (IQR 35.8 – 54.5 years) in Lisbon and Belo Horizonte, respectively. The number of 199 200 female participants was higher in both control groups when compared to infected 201 patients. The prevalence of comorbidities was higher in the Portuguese population, and 202 hypertension was the most prevalent among infected patients in both cities. Deaths and

missing samples were only registered in Lisbon (Table 1).

205 206

207

208

209210

211

212

213214

215216

217218

219

220

221

222

223

224225

226

227

228

229

230

231232

233234

235

236237

The inflammatory profiles of COVID-19 patients were distinct in the two cohorts Severe COVID-19 has been reported to be associated with accelerated senescence (Diao et al, 2020; Zheng et al, 2020). In order to understand the immunological profile expressed by the cohorts, we first compared the global production of inflammatory mediators between controls and infected patients in time zero (T0) and time seven (T7). As presented in radar charts (Fig. 1A), there was an overall increase in the frequency of high producers of serum mediators in the infected group from Portugal in TO when compared to the control group, confirming the ongoing response to the infection. Notably there was an increase in the frequency of high producers of mediators involved in inflammatory response, such as IL-4, IL-6, IFN- γ , TNF, CXCL-5. Seven days after hospitalization, the immune response was still more prominent than in non-infected individuals, despite the reduction in the frequency of high producers of IL-4, CCL-2, IFN-γ and TNF, possibly indicating a tendency towards resolution of the inflammatory response. Corroborating this result, a significant reduction in the production of CCL-2, IFN-γ, IL-6 and IL-10 was also observed (Fig. 1B). Similar to the analysis conducted for Lisbon patients, to assess whether a population composed of younger individuals from Brazil, who developed moderate to severe clinical conditions, presented a similar pattern of longitudinal immunological response, we compared the overall inflammatory profile of control and infected patients (Fig. 1C). As expected, the control group presented a very discreet production of mediators, while infected individuals showed a burst in inflammation throughout the study. When comparing T0 and T7, there was a rise in the frequency of high producers of many cytokines, including CXCL-8, IL-10, IL-2, GM-CSF, IL-4, IFN-γ, and IL-12p70, indicating intensification in the inflammatory response. Meanwhile, IL-13 presented a reduction in its frequency (Fig 1C). No significant change in the levels of these mediators was observed within seven days. Longitudinal correlation analysis of immunological mediators allowed us to gain insights into cytokines, chemokines, and growth factors production during hospitalization (Fig. 2A). In the Lisbon cohort, although we observed a reduction in the number and intensity of correlations, there was a remarkable switch from positive to negative interactions between mediators, notably in CXCL-2, CCL-2, IL-6, IL-12p70, INF-γ, and IL-4. Some mediators, such as IL-2, GM-CSF and IL-13 gained interactions in T7 (Fig. 2A).

- 238 The correlation matrix graphic representation from Brazil showed a decline in some
- interactions within seven days. There is an evident loss of positive correlations for IL-6,
- 240 IL-10, TNF, and IL-12p70, with the latter having also gained negative correlations,
- 241 notably with CXCL-8, IL-β, IL-1ra, and INF-γ (Fig. 2C). On the other hand, CCL-2,
- 242 IFN-γ, and GM-CSF gained intensity and significance in numerous interactions (Fig.
- 243 2C). Interestingly, we see an increase in the total number of significant correlations
- between age and cytokines, mostly negative ones, which could indicate a reduction in
- the interactions with aging.

- 247 Exhausted and immunosenescent T cells accumulate in COVID-19 patients of both
- 248 *cohorts regardless of disease severity*
- 249 Since inflammatory response during COVID-19 infection is already associated with T
- 250 cell exhaustion (Arcanjo et al, 2021; Lee et al, 2021), we used flow cytometry
- 251 immunophenotyping to evaluate alterations in immune responses throughout the course
- of infection. We investigated the evolution of the relative abundance of CD4⁺ and CD8⁺
- 253 T cells using manual gating as described in Supplementary Figure 1. T cell markers
- related to differentiation (CD28, CCR7, CD45RO) and senescence/exhaustion (CD57,
- 255 KLRG1, PD-1) allowed us to identify these phenotypes in distinct cell compartments
- 256 including naïve (CD28⁺CCR7⁺CD45RO⁻) and effector memory (CD28⁻CCR7⁻
- 257 $CD45RO^+$) T cells.
- 258 Results from Lisbon patients showed an increase in the frequency of differentiated T
- 259 CD4⁺ cells (CD28) expressing both markers of senescence/exhaustion
- 260 (CD57⁺KLRG1⁺) as well as effect memory cells (EM) (CD45RO+ CCR7- CD28-) (Fig.
- 3 C and E). In the CD28-CD8⁺ T cell compartment, frequency CD57⁺KLRG1⁺ cells
- increased while there was no difference in EM subset (Fig. 3 D and F).
- 263 Contrary to what was observed in severe cases from Lisbon, frequencies of naïve CD4⁺
- and CD8⁺ T cells from patients in Brazil reduced during hospitalization (Fig 3 G and
- 265 H). This change was accompanied by an increase in T CD4⁺CD28⁻ and EM cells
- double-positive for CD57⁺KLRG1⁺ during seven days (Fig. 3 I and K). It was also
- observed a reduction in the frequency of FOXP3⁺ CD4⁺ T cells in the individuals from
- the Brazilian cohort whereas no difference was observed in the frequency of PD-1-
- expressing (exhausted) FOXP3⁺ CD4⁺ T (Fig S2).

270 Altogether our results show an emergence of an increased senescent/exhausted T cell phenotype in patients with COVID-19 during 7 days of infection regardless of disease 271 272 severity. 273 274 **Discussion** 275 Inflammation induced by viral infections plays an important role in the differentiation 276 and development of T cells, as they induce extensive cell proliferation, however it can 277 ultimately lead to cell exhaustion and senescence (Wherry, 2011; Moro-Garcia et al, 278 2018; Heath & Grant, 2020). Although this phenomenon is mainly related to chronic 279 infections such as CMV, HIV, HBV and HPV (Fulop, Larbic, Pawelec, 2013; Wherry, 280 2011), it has also been identified in patients with acute SARS-Cov-2 infection (De Biase et al, 2020; Arcanjo et al, 2021). Considering these findings and the highly 281 282 heterogeneous immunological responses observed in COVID-19 (Lucas et al, 2020), we studied the evolution of the inflammatory response and exhaustion/senescence T cell 283 284 profile in a seven-day interval in two different cohorts of infected individuals (one from 285 Belo Horizonte, Brazil and another one from Lisbon, Portugal). 286 Our longitudinal analysis revealed different inflammatory profiles between cohorts, 287 although both presented a hyperactivation of the immune system in response to the infection. At admission, the severe patients from Portugal exhibited high levels of 288 biomarkers associated with a core response signature in moderate to severe conditions 289 in COVID-19, such as IFN-y, TNF, IL-6, and IL-10 (Liu et al, 2020; Lucas et al, 2020). 290 291 Meanwhile, over the seven-day period, there was a trend towards the reduction of the 292 inflammatory profile, as observed by the decrease in all cytokine levels (Fig. 1A). This 293 data is supported by the significant reduction of IL-2, IFN-γ, and IL-6 (Fig. 1B), which 294 are biomarkers related to hyperactivation of T cells and recruitment of macrophages to 295 the site of infection (Arcanjo et al, 2021; Coperchini et al, 2021). Decrease in the antiinflammatory cytokine IL-10 accompanies the general decline in inflammatory immune 296 297 response. The emergence of negative correlations in the correlation matrix also suggests 298 the downregulation of the immune response during the course of the disease (Fig. 2B), 299 indicating a tendency to resolution of the inflammatory response. 300 Patients from Brazil with mild to severe disease had a trend towards a global rise in 301 serum cytokine production (Fig. 1C). For instance, the frequency of high producers of 302 CXCL-8, a chemokine involved in the recruitment of neutrophils to the site of infection 303 and commonly elevated in patients with COVID-19 (Coperchini et al, 2020; Sallenave

& Guillot, 2020; Hazeldine & Lord, 2021), suggests an enhancement of the 304 305 inflammatory response in the course of seven days (Fig 1C). Also, the correlation 306 matrix evidenced higher correlations between CCL-2, IFN-γ, and GM-CSF levels in T7. 307 These mediators are implicated in T lymphocyte response to SARS-CoV-2, such as cell trafficking, cytokine production and cell replication (Coperchini et al, 2020; Arcanjo et 308 al, 2021). Considering that disease is associated with the loss of complexity and 309 310 dynamics of physiological processes (Lipsitz, 2004), the reduction in some correlations 311 after a week indicates a putative imbalance in the immune network complexity 312 developed during this short period of infection (Fig 2A). As a complement to the inflammatory profile found in COVID-19 patients from Brazil, 313 we also observed a reduction in the frequency of Foxp3⁺CD4⁺ T cells which have been 314 widely described as regulatory cells mediating anti-inflammatory effects. Of note, 315 316 frequency of Foxp3⁺CD4⁺ T cells expressing the exhaustion marker PD-1 did not change suggesting that only functionally active regulatory T cells were affected by the 317 318 infection. These data are in accordance with previous reports showing a reduction in the 319 frequency of these T cell subset in patients with COVID-19 namely in patients with a 320 severe form of the disease (Lucas et al, 2020). It is possible that the two cohorts, in Brazil and Lisbon, were not exactly synchronized. 321 In fact, we observed a more marked reduction of pro-inflammatory cytokines between 322 day 0 and 7 in the Lisbon cohort. However, although this heterogeneity may sound as a 323 324 negative feature of our sample, the similar results yielded by the two distinct cohorts 325 regarding the immunosenescence profile of the T cell compartment helped to reveal a 326 common phenomenon associated with SARS-CoV2 infection. 327 Studies on individuals with severe COVID-19 revealed an increase in T cells expressing markers of exhaustion/senescence such as PD-1, TIGIT, and CD57, especially in the 328 329 CD8 compartment, when compared to healthy individuals (Zheng et al., 2020a; Zheng 330 et al, 2020b; De Biasi, 2020; Arcanjo et al, 2021). In the present work, our aim was to examine the emergence of these alterations in a longitudinal study and to determine 331 332 whether these immunosenescence alterations were restricted to severe cases of the 333 disease in two distinct cohorts. Our data show that patients with mild and severe cases 334 of COVID-19 in Brazil had an increase in CD4⁺CD28⁻ T cells expressing both CD57 335 and KLRG1, whereas patients from Lisbon with severe disease showed this increase in 336 both CD4⁺CD28⁻ and CD8⁺CD28⁻ T cell compartments (Fig 3 C, D, I). Expression of 337 CD57 and KLRG1, and the loss of the CD28 molecule are considered indicators of

340 341

342

343344

345

346

347

348

349 350

351

352

353

354

355

356

357 358

359

360

361

362

363 364

365 366

367 368

369

370

terminal differentiation and are associated with the senescence profile of T lymphocytes (Akbar & Henson, 2011; Pangrazzi & Weinberger, 2020). Although the KLRG1 molecule also emerges on the cell surface after differentiation, the signalling generated by this molecule regulates a pathway related to exhaustion, making it a marker of cellular senescence and exhaustion (Akbar & Hsenson, 2011; Wherry & Kurachi, 2015; Pinti et al, 2016; Cunha et al, 2020; Pangrazzi & Weinberger, 2020). Therefore, absence of CD28 and the high expression of CD57 as well as KLRG1 provide what could be considered the best description of a senescent state (Rodriguez et al, 2021). Interestingly, our results identified the emergence of a senescence profile of T lymphocytes in individuals with COVID-19, both in mild/moderate and severe conditions, being more pronounced the more intense the inflammatory response to the disease was. Although there is no data in the literature relating inflammation and immunosenescence in COVID-19, the hyperactivation of the inflammatory response to SARS-CoV-2 infection has been associated with more severe disease (Lucas et al, 2020), which could possibly justify the increase in the frequency of terminally differentiated cells in this group of patients. It is also important to highlight that the cohort of critically ill patients from Portugal is mainly composed of elderly individuals. Thus, this may explain the difference between health conditions between Brazilian and Portuguese cohort samples. As predicted by our group and by others, immunosenescence and inflammaging may be aggravated by, but also may aggravate SARS-CoV-2 infection (Batista et al, 2020; Witkowski, Fulop, Bryl, 2022). The primary setting and one of the hallmarks of immunosenescence is thymic involution, which is followed by the reduction in the naïve cell output (Thomas, Wang, Su, 2020; Elyahu & Monsonego, 2021), a phenomenon that should have been affecting these patients even before the onset of the infection. This could be the reason why no difference was observed in the naïve T cell subset in this severely diseased elder group. The differences seen in inflammatory biomarkers between patients of Brazil and Portugal may be related to the time of the onset of symptoms, as the recruitment was carried out based on the moment patients sought medical assistance at the hospital, rather than on the initiation of symptoms. Notably, accumulation of exhausted/senescent cells seems to occur at distinct time points of disease development, indicating a process that could start early in infection and develop further than the 7-day period examined, 371 particularly in Brazil where the patients were recruited sooner regarding the course of 372 the disease. 373 There were limitations in this study, mainly the small sample size in both cohorts. This 374 may have hindered the identification of significant differences in inflammatory mediators and other T-cell subsets that would be possible using a larger number of 375 individuals. Moreover, this feature precluded formal statistical analysis regarding the 376 377 associations between laboratory findings and disease severity. There were also 378 methodological differences in the study of the two cohorts that could have impacted on 379 the results. We did not investigate the SARS-CoV-2 variant infecting the individuals and this could also partially explain differences in their immunological responses, 380 381 considering the distinct scenarios of the pandemic in Brazil and Portugal during which 382 patients were recruited. 383 Our longitudinal study provided evidence of accelerated immunosenescence in the T cell compartment during COVID-19 showing that senescent and exhausted T cells 384 385 significantly increased within a seven-day period. Interestingly, even though our 386 samples were composed by two different populations, who presented distinct inflammatory profiles and were possibly affected by different variants of the virus, a 387 388 similar profile of immunossenescence and exhaustion was identified during this short period of infection by SARS-CoV-2. Furthermore, this change in immunological 389 390 profile was shown to be independent of disease severity even though the magnitude was 391 greater in patients with severe disease. This suggests that accelerated 392 immunosenescence of the T cell compartment may be described as a general feature of 393 COVID-19. 394 395 **Acknowledgments:** This study was financially supported by grants from Fundação para 396 a Ciência e a Tecnologia (FCT, Portugal, Research4covid_369), Merck Sharp & Dohme 397 (MISP 42521) and Conselho Nacional de Desenvolvimento Científico e Tecnológico 398 Brazil, APQ 407363/2021-1). RB Pedroso is funded 399 (SFRH/BD/144372/2019). Samples in Lisbon were collected, stored and provided by 400 Biobanco-iMM (Lisbon Academic Medical Center, Lisbon, Portugal) in coordination 401 with a taskforce created at iMM for the collection of COVID-19 Research Samples. 402 Flow cytometry in Lisbon was performed at the Flow Cytometry Facility of iMM.

Conflict of interest: The authors have no conflict of interest.

References

405

- 1. Aiello A, Farzaneh F, Candore G, Caruso C, Davinelli S, Gambino CM, Ligotti
- ME, Zareian N, Accardi G. Immunosenescence and Its Hallmarks: How to
- Oppose Aging Strategically? A Review of Potential Options for Therapeutic
- Intervention. Front Immunol. 2019, 10: 2247. doi: 10.3389/fimmu.2019.02247.
- 411 PMID: 31608061; PMCID: PMC6773825.
- 412 2. Akbar AN, Henson SM. Are senescence and exhaustion intertwined or unrelated
- processes that compromise immunity? *Nat Rev Immunol.* 2011, 11(4):289-95.
- doi: 10.1038/nri2959. PMID: 21436838.
- 3. Arcanjo A, Pinto KG, Logullo J, Leite PEC, Menezes CCB, Freire-de-Lima L,
- 416 Diniz-Lima I, Decoté-Ricardo D, Rodrigues-da-Silva RN, Freire-de-Lima CG,
- Filardy AA, Lima-Junior JDC, Bertho AL, De Luca PM, Granjeiro JM, Barroso
- 418 SPC, Conceição-Silva F, Savino W, Morrot A. Critically ill COVID-19 patients
- 419 exhibit hyperactive cytokine responses associated with effector exhausted
- senescent T cells in acute infection. J Infect Dis. 2021: jiab425. doi:
- 421 10.1093/infdis/jiab425. PMID: 34427670; PMCID: PMC8513399.
- 4. Batista MA, Calvo-Fortes F, Silveira-Nunes G, et al. Inflammaging in Endemic
- Areas for Infectious Diseases. Front Immunol. 2020, 11: 579972.
- 424 doi:10.3389/fimmu.2020.579972.
- 5. Burki T. COVID-19 in Latin America. *Lancet Infect Dis.* 2020, 20(5):547-548.
- 426 doi:10.1016/S1473-3099(20)30303-0.
- 6. Camell CD, Yousefzadeh MJ, Zhu Y, Prata LGPL, Huggins MA, Pierson M,
- Zhang L, O'Kelly RD, Pirtskhalava T, Xun P, Ejima K, Xue A, Tripathi U,
- Espindola-Netto JM, Giorgadze N, Atkinson EJ, Inman CL, Johnson KO,
- 430 Cholensky SH, Carlson TW, LeBrasseur NK, Khosla S, O'Sullivan MG, Allison
- DB, Jameson SC, Meves A, Li M, Prakash YS, Chiarella SE, Hamilton SE,
- Tchkonia T, Niedernhofer LJ, Kirkland JL, Robbins PD. Senolytics reduce
- coronavirus-related mortality in old mice. *Science*. 2021, 373(6552): eabe4832.
- doi: 10.1126/science.abe4832. PMID: 34103349; PMCID: PMC8607935.
- 7. Chen YM, Zheng Y, Yu Y, Wang Y, Huang Q, Qian F, Sun L, Song ZG, Chen
- Z, Feng J, An Y, Yang J, Su Z, Sun S, Dai F, Chen Q, Lu Q, Li P, Ling Y, Yang
- Z, Tang H, Shi L, Jin L, Holmes EC, Ding C, Zhu TY, Zhang YZ. Blood
- 438 molecular markers associated with COVID-19 immunopathology and multi-

- organ damage. EMBO J. 2020, 39(24): e105896. doi:
- 440 10.15252/embj.2020105896. PMID: 33140861; PMCID: PMC7737620.
- 8. Cifuentes-Faura J. COVID-19 Mortality Rate and Its Incidence in Latin
- America: Dependence on Demographic and Economic Variables. *Int J Environ*
- 443 Res Public Health. 2021, 18(13):6900. doi:10.3390/ijerph18136900.
- 9. Coperchini F, Chiovato L, Ricci G, Croce L, Magri F, Rotondi M. The cytokine
- storm in COVID-19: Further advances in our understanding the role of specific
- chemokines involved. Cytokine Growth Factor Rev. 2021, 58: 82-91.
- doi:10.1016/j.cytogfr.2020.12.005.
- 10. Cunha LL, Perazzio SF, Azzi J, Cravedi P, Riella LV. Remodeling of the
- Immune Response with Aging: Immunosenescence and Its Potential Impact on
- 450 COVID-19 Immune Response. Front Immunol. 2020, 11: 1748. doi:
- 451 10.3389/fimmu.2020.01748. PMID: 32849623; PMCID: PMC7427491.
- 452 11. De Biasi S, Meschiari M, Gibellini L, Bellinazzi C, Borella R, Fidanza L, Gozzi
- L, Iannone A, Lo Tartaro D, Mattioli M, Paolini A, Menozzi M, Milić J,
- Franceschi G, Fantini R, Tonelli R, Sita M, Sarti M, Trenti T, Brugioni L,
- Cicchetti L, Facchinetti F, Pietrangelo A, Clini E, Girardis M, Guaraldi G,
- 456 Mussini C, Cossarizza A. Marked T cell activation, senescence, exhaustion and
- skewing towards TH17 in patients with COVID-19 pneumonia. *Nat Commun.*
- 458 2020, 11(1): 3434. doi: 10.1038/s41467-020-17292-4. PMID: 32632085;
- 459 PMCID: PMC7338513.
- 12. Diao B, Wang C, Tan Y, Chen X, Liu Y, Ning L, Chen L, Li M, Liu Y, Wang
- 461 G, Yuan Z, Feng Z, Zhang Y, Wu Y, Chen Y. Reduction and Functional
- Exhaustion of T Cells in Patients with Coronavirus Disease 2019 (COVID-19).
- 463 Front Immunol. 2020, 11: 827. doi: 10.3389/fimmu.2020.00827. PMID:
- 464 32425950; PMCID: PMC7205903.
- 465 13. Elyahu Y, Monsonego A. Thymus involution sets the clock of the aging T-cell
- landscape: Implications for declined immunity and tissue repair. Ageing Res
- 467 Rev. 2021, 65: 101231. doi: 10.1016/j.arr.2020.101231. PMID: 33248315.
- 468 14. Fülöp T, Larbi A, Dupuis G, Le Page A, Frost EH, Cohen AA, Witkowski JM,
- Franceschi C. Immunosenescence and Inflamm-Aging as Two Sides of the Same
- 470 Coin: Friends or Foes? Front Immunol. 2018, 8:1960. doi:
- 471 10.3389/fimmu.2017.01960. PMID: 29375577; PMCID: PMC5767595.

- 15. Fülöp T, Larbi A, Pawelec G. Human T cell aging and the impact of persistent
- viral infections. *Front Immunol.* 2013; 4:271. doi:10.3389/fimmu.2013.00271.
- 16. Goronzy JJ, Weyand CM. Mechanisms underlying T cell ageing. *Nat Rev*
- 475 *Immunol.* 2019, 19(9): 573-583. doi: 10.1038/s41577-019-0180-1. PMID:
- 476 31186548; PMCID: PMC7584388.
- 17. Guo W, Li M, Dong Y, et al. Diabetes is a risk factor for the progression and
- 478 prognosis of COVID-19. Diabetes/Metabolism Research and
- 479 *Reviews*. 2020; 36: e3319. https://doi.org/10.1002/dmrr.3319.
- 18. Hassouneh F, Campos C, López-Sejas N, Alonso C, Tarazona R, Solana R, Pera
- A. Effect of age and latent CMV infection on CD8+□CD56+ T cells (NKT-like)
- frequency and functionality. Mech Ageing Dev. 2016, 158: 38-45. doi:
- 483 10.1016/j.mad.2015.12.003. PMID: 26751040.
- 19. Hazeldine J, Lord JM. Neutrophils and COVID-19: Active Participants and
- Rational Therapeutic Targets. Front Immunol. 2021, 12: 680134. doi:
- 486 10.3389/fimmu.2021.680134. PMID: 34149717; PMCID: PMC8206563.
- 487 20. Heath J J, Grant D M. The Immune Response Against Human Cytomegalovirus
- Links Cellular to Systemic Senescence. Cells. 2020, 9(3): 766. doi:
- 489 10.3390/cells9030766. PMID: 32245117; PMCID: PMC7140628.
- 490 21. Lee S, Yu Y, Trimpert J, Benthani F, Mairhofer M, Richter-Pechanska P, Wyler
- 491 E, Belenki D, Kaltenbrunner S, Pammer M, Kausche L, Firsching TC, Dietert K,
- Schotsaert M, Martínez-Romero C, Singh G, Kunz S, Niemeyer D, Ghanem R,
- Salzer HJF, Paar C, Mülleder M, Uccellini M, Michaelis EG, Khan A, Lau A,
- 494 Schönlein M, Habringer A, Tomasits J, Adler JM, Kimeswenger S, Gruber AD,
- 495 Hoetzenecker W, Steinkellner H, Purfürst B, Motz R, Di Pierro F, Lamprecht B,
- Osterrieder N, Landthaler M, Drosten C, García-Sastre A, Langer R, Ralser M,
- 497 Eils R, Reimann M, Fan DNY, Schmitt CA. Virus-induced senescence is a
- 498 driver and therapeutic target in COVID-19. *Nature*. 2021, 599(7884):283-289.
- 499 doi: 10.1038/s41586-021-03995-1. PMID: 34517409.
- 500 22. Li B, Yang J, Zhao F, et al. Prevalence and impact of cardiovascular metabolic
- diseases on COVID-19 in China. Clin Res Cardiol. 2020; 1–
- 502 8. https://doi.org/10.1007/s00392-020-01626-9.

- 23. Lipsitz L. A. (2004). Physiological complexity, aging, and the path to frailty.
- Science of aging knowledge environment: SAGE KE, 2004 (16),
- pe16.https://doi.org/10.1126/sageke.2004.16.pe16.
- 506 24. Liu J, Li S, Liu J, Liang B, Wang X, Wang H, Li W, Tong Q, Yi J, Zhao L,
- Xiong L, Guo C, Tian J, Luo J, Yao J, Pang R, Shen H, Peng C, Liu T, Zhang Q,
- Wu J, Xu L, Lu S, Wang B, Weng Z, Han C, Zhu H, Zhou R, Zhou H, Chen X,
- Ye P, Zhu B, Wang L, Zhou W, He S, He Y, Jie S, Wei P, Zhang J, Lu Y, Wang
- W, Zhang L, Li L, Zhou F, Wang J, Dittmer U, Lu M, Hu Y, Yang D, Zheng X.
- Longitudinal characteristics of lymphocyte responses and cytokine profiles in
- the peripheral blood of SARS-CoV-2 infected patients. *EBioMedicine* 2020, 55:
- 513 102763. doi: 10.1016/j.ebiom.2020.102763. PMID: 32361250; PMCID:
- 514 PMC7165294.
- 515 25. Lucas, C., Wong, P., Klein, J., Castro, T. B. R., Silva, J., Sundaram, M.,
- Ellingson, M. K., Mao, T., Oh, J. E., Israelow, B., Takahashi, T., Tokuyama, M.,
- Lu, P., Venkataraman, A., Park, A., Mohanty, S., Wang, H., Wyllie, A. L.,
- Vogels, C. B. F., Iwasaki, A. Longitudinal analyses reveal immunological
- 519 misfiring in severe COVID-19. *Nature*, 2020, 584, 463.
- 520 https://doi.org/10.1038/s41586-020-2588-y
- 521 26. Luiza-Silva, M., Campi-Azevedo, A. C., Batista, M. A., Martins, M. A., Avelar,
- 522 R. S., da Silveira Lemos, D., et al. Cytokine signatures of innate and adaptive
- 523 immunity in 17DD yellow fever vaccinated children and its association with the
- level of neutralizing antibody. J. Infect. Dis. 2011, 204, 873-883. doi:
- 525 10.1093/infdis/jir439
- 526 27. Moro-García MA, Mayo JC, Sainz RM, Alonso-Arias R. Influence of
- Inflammation in the Process of T Lymphocyte Differentiation: Proliferative,
- Metabolic, and Oxidative Changes. Front Immunol. 2018, 9:339. doi:
- 529 10.3389/fimmu.2018.00339. PMID: 29545794; PMCID: PMC5839096.
- 530 28. Mulchandani R, Lyngdoh T, Kakkar AK. Deciphering the COVID-19 cytokine
- storm: Systematic review and meta-analysis. Eur J Clin Invest. 2021, 51(1):
- e13429. doi:10.1111/eci.13429.
- 533 29. Mueller AL, McNamara MS, Sinclair DA. Why does COVID-19
- disproportionately affect older people? Aging 2020, 12:9959-9981.
- 535 https://doi.org/10.18632/aging.103344.

- 536 30. Osuchowski MF, Winkler MS, Skirecki T, Cajander S, Shankar-Hari M,
- Lachmann G, Monneret G, Venet F, Bauer M, Brunkhorst FM, Weis S, Garcia-
- Salido A, Kox M, Cavaillon JM, Uhle F, Weigand MA, Flohé SB, Wiersinga
- WJ, Almansa R, de la Fuente A, Martin-Loeches I, Meisel C, Spinetti T,
- Schefold JC, Cilloniz C, Torres A, Giamarellos-Bourboulis EJ, Ferrer R,
- Girardis M, Cossarizza A, Netea MG, van der Poll T, Bermejo-Martín JF, Rubio
- I. The COVID-19 puzzle: deciphering pathophysiology and phenotypes of a new
- disease entity. Lancet Respir Med. 2021, 9(6): 622-642. doi: 10.1016/S2213-
- 544 2600(21)00218-6. PMID: 33965003; PMCID: PMC8102044.
- 31. Pangrazzi L, Weinberger B. T cells, aging and senescence. *Exp Gerontol.* 2020,
- 546 134:110887. doi: 10.1016/j.exger.2020.110887. PMID: 32092501.
- 32. Pinti M, Appay V, Campisi J, Frasca D, Fülöp T, Sauce D, Larbi A, Weinberger
- B, Cossarizza A. Aging of the immune system: Focus on inflammation and
- 549 vaccination. Eur J Immunol, 2016, 46(10): 2286-2301. doi:
- 550 10.1002/eji.201546178. PMID: 27595500; PMCID: PMC5156481.
- 33. Rahman A, Sathi NJ. Risk factors of the severity of COVID-19: A meta-
- analysis. *Int J Clin Pract*. 2021, 75(7): e13916. doi: 10.1111/ijcp.13916. Epub
- 553 2020 Dec 20. PMID: 33372407.
- 34. Rodriguez IJ, Lalinde Ruiz N, Llano León M, et al. Immunosenescence Study of
- T Cells: A Systematic Review. Front Immunol. 2021, 11:604591. Published
- 556 2021 Jan 15. doi:10.3389/fimmu.2020.604591.
- 557 35. Sallenave JM, Guillot L. Innate Immune Signaling and Proteolytic Pathways in
- the Resolution or Exacerbation of SARS-CoV-2 in Covid-19: Key Therapeutic
- Targets? Front Immunol. 2020, 11:1229. doi: 10.3389/fimmu.2020.01229.
- 560 PMID: 32574272; PMCID: PMC7270404.
- 36. Solana R, Tarazona R, Aiello AE, Akbar AN, Appay V, Beswick M, Bosch JA,
- 562 Campos C, Cantisán S, Cicin-Sain L, Derhovanessian E, Ferrando-Martínez S,
- Frasca D, Fulöp T, Govind S, Grubeck-Loebenstein B, Hill A, Hurme M, Kern
- F, Larbi A, López-Botet M, Maier AB, McElhaney JE, Moss P, Naumova E,
- Nikolich-Zugich J, Pera A, Rector JL, Riddell N, Sanchez-Correa B, Sansoni P,
- Sauce D, van Lier R, Wang GC, Wills MR, Zieliński M, Pawelec G. CMV and
- Immunosenescence: from basics to clinics. *Immun Ageing* 2012, 9(1): 23. doi:
- 568 10.1186/1742-4933-9-23. PMID: 23114110; PMCID: PMC3585851.

- 37. Thakur, B., Dubey, P., Benitez, J. et al. A systematic review and meta-analysis
- of geographic differences in comorbidities and associated severity and mortality
- 571 among individuals with COVID-19. Sci. Rep 2021, 11, 8562.
- 572 <u>https://doi.org/10.1038/s41598-021-88130-w</u>.
- 573 38. Thomas R, Wang W, Su DM. Contributions of Age-Related Thymic Involution
- to Immunosenescence and Inflammaging. Immun Ageing 2020, 17:2. doi:
- 575 10.1186/s12979-020-0173-8. PMID: 31988649; PMCID: PMC6971920.
- 39. (a) WHO COVID-19 Dashboard. Geneva: World Health Organization, 2020.
- Available online: https://covid19.who.int/ (Access: April 4th 2022).
- 578 40. (b) WHO Working Group on the Clinical Characterisation and Management of
- 579 COVID-19 infection. A minimal common outcome measure set for COVID-19
- clinical research. Lancet Infect Dis. 2020 Aug;20(8):e192-e197. doi:
- 581 10.1016/S1473-3099(20)30483-7. Epub 2020 Jun 12. Erratum in: *Lancet Infect*
- 582 *Dis.* 2020, 20(10): e250. PMID: 32539990; PMCID: PMC7292605.
- 41. Witkowski JM, Fulop T, Bryl E. Immunosenescence and COVID-19. Mech
- 584 Ageing Dev. 2022, 204:111672. doi: 10.1016/j.mad.2022.111672.. PMID:
- 585 35378106
- 586 42. Wu C, Chen X, Cai Y, Xia J, Zhou X, Xu S, Huang H, Zhang L, Zhou X, Du C,
- Zhang Y, Song J, Wang S, Chao Y, Yang Z, Xu J, Zhou X, Chen D, Xiong W,
- 588 Xu L, Zhou F, Jiang J, Bai C, Zheng J, Song Y. Risk Factors Associated With
- Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus
- Disease 2019 Pneumonia in Wuhan, China. JAMA Intern Med. 2020 Jul
- 591 1;180(7):934-943. doi: 10.1001/jamainternmed.2020.0994. Erratum in: JAMA
- 592 Intern Med. 2020 Jul 1;180(7):1031. PMID: 32167524; PMCID: PMC7070509.
- 593 43. Wherry EJ. T cell exhaustion. *Nat Immunol* 2011, 12(6): 492-9. doi:
- 594 10.1038/ni.2035. PMID: 21739672.
- 595 44. Wherry EJ, Kurachi M. Molecular and cellular insights into T cell
- 596 exhaustion. *Nat Rev Immunol*. 2015, 15(8): 486-499. doi:10.1038/nri3862.
- 597 45. Xu L, Chen G. Risk factors for severe corona virus disease 2019 (COVID-19)
- 598 patients: a systematic review and meta
- analysis. *medRxiv*. 2020. https://doi.org/10.1101/2020.03.30.20047415.

46. (a) Zheng M, Gao Y, Wang G, et al. Functional exhaustion of antiviral lymphocytes in COVID-19 patients. *Cell Mol Immunol.* 2020, 17(5): 533-535. doi:10.1038/s41423-020-0402-2.

- 47. (b) Zheng, HY., Zhang, M., Yang, CX. et al. Elevated exhaustion levels and reduced functional diversity of T cells in peripheral blood may predict severe progression in COVID-19 patients. *Cell Mol Immunol* 2020, 17, 541–543 (2020). https://doi.org/10.1038/s41423-020-0401-3.
- 48. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *The Lancet* 2020, 395(10229): 1054 1062.

Figure Legends:

603

604 605

606

607

608

609 610

611612

613

614 615

616

617

618

619

620

621

622

623 624

625 626

627

628 629

630

631

632

Figure 1 – Longitudinal study of inflammatory profiles of COVID-19 patients

from Portugal and Brazil during a seven-day period of disease development.

(A) Radar chart of serum mediators of control group (baseline) and patients with

COVID-19 at hospitalization (T0) and seven days later (T7) in the Portuguese

cohort. (B) Comparison of serum levels of CCL-2, IFN-γ, IL-6 and IL-10 at hospital

admission (T0) and seven days later (T7). Wilcoxon test was applied to compare

samples of the same patient at T0 and T7. P < 0.05. (C) Radar chart representing the

balance in frequencies of inflammatory and anti-inflammatory

cytokines/chemokines in the innate and adaptive immunity compartments from

individuals between the time of recruitment (T0) at the hospital/ambulatory and

seven days later (T7) in the Brazilian cohort.

Figure 2 - Spearman's correlation correlogram of the inflammatory profile of

COVID-19 patients at day 0 and 7 of disease development. (A) Correlation

matrices across all cytokines/chemokines from patients' sera, comparing COVID-19

at time zero (T0) of infection and 7 days later (T7) in Lisbon, Portugal, and (B) Belo

Horizonte, Brazil. Positive cytokine correlations are lost, and negative correlations

appear going from T0 to T7. The strength of the correlation between two variables is

represented by the color of the circle at the intersection of those variables. Colors

range from dark blue (strong positive correlation, i.e. r2 = 1.0) to dark red (strong

634 635

636

637

638

639 640

641

642

643

644

645 646

647 648

649 650

651

652 653

654

655 656

657 658

659

negative correlation; i.e. r2 = -1.0). Results were not displayed if not significant (P < 0.05) according to Spearman Correlation Test. Figure 3 -Frequencies of exhausted/senescent T cells in patients with mild to severe COVID-19 from Portugal and Brazil during a seven-day period. Representative flow cytometry plots of gated cell subsets and frequency analysis at time 0 and 7. (A and B) Frequencies of naïve CD4 and CD8 T cell in individuals from Lisbon. (C, D, E and F) Differentiated CD4+ and CD8+ T cells presenting senescence/exhaustion markers CD57 and KRLG1 obtained by manual gating in Portuguese patients. (G-L) Percentage of CD4+ and CD8+CD28-CD45RO+CCR7-(effector memory) expressing senescence/exhaustion markers in Brazilian patients. Statistical analysis was performed using the nonparametric Wilcoxon rank-sum. P < 0.05. Figure S1 - Gating strategy used to identify the profile of exhausted and senescent CD8+ and CD4+ T cells. (A) T cells were characterized based on their CD3 and CD4 expression, and then categorized by CD45RO, CCR7, CD28, CD57 and KLRG1 expression. Regulatory T cells expressing FOXP3 were assessed in Brazilian population for their PD-1 expression. (B) CD8 Gate strategy for analysis of CD8+ T cells was similar to the one used for CD4+ T cells. Figure S2 - SARS-CoV-2 infection decreases the frequency of FOXP3+CD4+T cells in Brazilian patients with mild to severe COVID-19 in a seven-day period. Percentage of T CD4+CD25+FOXP3+ cells obtained by manual gating. Frequency of cells expressing exhaustion marker PD-1. Statistical analysis was performed using the nonparametric Wilcoxon rank-sum. P < 0.05





Figure 1






Figure 2

TIME ZERO TIME SEVEN

CD57

CD57

Figure 3

TIME ZERO TIME SEVEN

 Table 1 - Clinical characteristics of Lisbon and Belo Horizonte populations.

	Lisbon		Belo Horizonte	
	Healthy controls (n=10)	COVID-19 (n=20)	Healthy controls (n=5)	COVID-19 (n=8)
Age, median (IQR) (years)	66.0 (57.8 – 74.5)	69.0 (60.0 – 84.3)	25.0 (22.0 – 29.0)	42.5 (35.8 – 54.5)
Female sex (%)	9 (90%)	6 (30%)	4 (80%)	4 (50%)
Comorbidities, n (%)				
Cancer	0	0	0	1 (12.5%)
Cardiovascular disease	0	5 (25%)	0	0
Diabetes	0	6 (30%)	0	0
High cholesterol	0	3 (15%)	0	0
Hypertension	0	12 (60%)	0	1 (12.5%)
Disease severity, n (%)				
Mild	NA	0	NA	3 (37.5%)
Moderate	NA	0	NA	3 (37.5%)
Severe	NA	20 (100%)	NA	2 (25%)
Death during hospitalization, n (%)	NA	3 (7.5%)	NA	0
Samples lost between T0 and T7, n (%)	NA	6 (15%)	NA	0

IQR: interquartile range. NA: not applicable.